Tech Company Financing Transactions
Neotropix Funding Round
On 6/30/2005, Neotropix announced $3.8 million in financing from Aurora Funds, Novartis BioVenture Fund and Quaker Partners.
Transaction Overview
Company Name
Announced On
6/30/2005
Transaction Type
Venture Equity
Amount
$3,800,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
351 Phoenixville Pike
Malvern, PA 19355
USA
Malvern, PA 19355
USA
Phone
Website
Email Address
Overview
Neotropix is an early stage drug discovery company dedicated to the research, development and commercialization of virus-based therapies for the treatment of cancer. Founded in 2003, Neotropix is developing oncolytic virotherapies to treat several of the most aggressive and deadly forms of cancer.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Peter Lanciano
Chief Scientific Officer
Paul Hallenbeck
Browse more venture capital transactions:
Prev: 6/30/2005: Cadence Pharmaceuticals venture capital transaction
Next: 6/30/2005: Multispectral Imaging venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs